Correlation of long non-coding RNA <i>H19</i> expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma

Qi Wang(Chengdu University of Traditional Chinese Medicine), Caicun Zhou(Tongji University), Ningning Cheng(Tongji University), Xuefei Li(Harbin Medical University), Hui Pan(Université Paris Cité), Chunyu Li(Tianjin University of Traditional Chinese Medicine), Limin Zhang(Wuhan Institute of Physics and Mathematics), Chao Zhao(Tongji University), Shengxiang Ren(Tongji University), Weijing Cai(Hebei Medical University), Chunxia Su(Tongji University)
Oncotarget
November 29, 2016
10.18632/oncotarget.13708
Cited by 77

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467